https://www.selleckchem.com/products/jph203.html
98], P=0.04; ACEi/ARBs and BB≥50% TD adjusted HR 0.54, 95% CI [0.30-0.96], P=0.03). With regard to treatment changes from admission to discharge, therapy was decreased in 258 (44.6%) patients, stable in 194 (33.6%), and increased in 126 (21.8%). Compared with patients with stable therapy, treatment intensification was associated with a lower rate of the primary endpoint (adjusted HR 0.49, 95% CI [0.29-0.83]; P=0.01). In patients with AHF, prescription of ACEi/ARBs/BB≥50% TD at the time of discharge, whether achieved or not through treatm
Like
Comment
Share
